Clinical experience of at-2266 in urinary tract infections

Kenji Oishi, Kenichiro Okada, Osamu Yosmida, Yoichi Arai, Takanobu Taniguchi

Research output: Contribution to journalArticle

Abstract

AT-2266 was orally administered to a total of 31 patients to investigate its therapeutic efficacy. It was administered toll patients with acute simple cystitis mainly in doses of 300 mg daily for 4 days and to 20 patients with complicated urinary tract infection (UTI) mainly in doses of 600 mg daily for 4-14 days. Of 26 patients in whom drug efficacy was evaluated, 16 met the Criteria for Clinical Evaluation in UTI. In acute simple cystitis, according to the Criteria for Clinical Evaluation in UTI, pyuria was cleared in 3 cases (75%) and unchanged in 1 case (25%): bacteriuria were eliminated in 4 cases (100%); and overall clinical efficacy was rated excellent in 3 cases (75%) and moderate in 1 case (25%), i. e. favorable responses were obtained in all cases. In complicated urinary tract infection, pyuria was cleared in 5 cases (41.7%), decreased in 3 cases (25.0%) and unchanged in 4 cases (33.3%); bacteriuria were eliminated in 11 cases (91.6%), replaced in 1 case (8.3%): and overall clinical efficacy was rated excellent in 5 cases (41.7%), moderate in 7 cases (58.3%), and the success rate was 100%. The results of the doctor's efficacy evaluation was similar to those obtained according to the Criteria for Clinical Evaluation in UTI. Side effects were encountered in 4 (12.8%) of 31 cases. Eruption was found in 3 patients, and headache, dizziness antinausea were reported by 1 patient. No patients showed abnormal BUN, creatinine, electrolytes, GOT, GPT or AI-P levels after AT-2266 treatment except those who had shown any abnormal value prior to treatment.

Original languageEnglish
Pages (from-to)766-775
Number of pages10
JournalChemotherapy
Volume32
Issue numberSupplement
DOIs
Publication statusPublished - 1984 Jan

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Clinical experience of at-2266 in urinary tract infections'. Together they form a unique fingerprint.

  • Cite this

    Oishi, K., Okada, K., Yosmida, O., Arai, Y., & Taniguchi, T. (1984). Clinical experience of at-2266 in urinary tract infections. Chemotherapy, 32(Supplement), 766-775. https://doi.org/10.11250/chemotherapy1953.32.Supplement3_766